Patents Assigned to National Jewish Medical Research Center
  • Patent number: 8765729
    Abstract: The present invention relates, in general, to cancer therapy, and, in particular, to a method of preventing or treating cancer using low molecular weight antioxidants (e.g., mimetics of superoxide dismutase (SOD)) as the active agent or as a chemo- and/or radio-protectant. The invention also relates to compounds and compositions suitable for use in such a method.
    Type: Grant
    Filed: November 9, 2006
    Date of Patent: July 1, 2014
    Assignees: Aeolus Sciences, Inc., Duke University, National Jewish Medical and Research Center
    Inventors: James D. Crapo, Brian J. Day, Ines Batinic-Haberle, Richard Gammans, Zeljko Vusjaskovic
  • Publication number: 20140162986
    Abstract: Methods for therapy of cystic fibrosis and other conditions are provided. The methods comprise one or more agents capable of increasing thiol-containing compound transport via a transporter system (i.e. ABC transporters such as MDR-1 or MRP-2) in cells. Other embodiments include the use of agents to modulate transport of thiol-containing compounds within the cell. Therapeutic methods involve the administration of such agents to a patient afflicted with cystic fibrosis and/or another condition responsive to stimulation of thiol-containing compound transport.
    Type: Application
    Filed: February 13, 2014
    Publication date: June 12, 2014
    Applicant: NATIONAL JEWISH MEDICAL AND RESEARCH CENTER
    Inventors: Brian J. Day, Leonard W. Velsor
  • Publication number: 20130177563
    Abstract: The present invention relates to methods of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cell. In particular, diseases or disorders including contact dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous T cell lymphoma, bullous pemphigoid, alopecia aereata, vitiligo, acne rosacea, prurigo nodularis, and herpes simplex virus, or combination thereof will benefit from the administration of an IL-31 antagonist. The invention also includes methods of predicting a therapeutically responsive patient population.
    Type: Application
    Filed: January 30, 2013
    Publication date: July 11, 2013
    Applicants: NATIONAL JEWISH MEDICAL RESEARCH CENTER, ZYMOGENETICS, INC.
    Inventors: ZYMOGENETICS, INC., NATIONAL JEWISH MEDICAL RESEARCH CENTER
  • Patent number: 8388964
    Abstract: The present invention relates to methods of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cell. In particular, diseases or disorders including contact dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous T cell lymphoma, bullous pemphigoid, alopecia aereata, vitiligo, acne rosacea, prurigo nodularis, and herpes simplex virus, or combination thereof will benefit from the administration of an IL-31 antagonist. The invention also includes methods of predicting a therapeutically responsive patient population.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: March 5, 2013
    Assignees: ZymoGenetics, Inc., National Jewish Medical Research Center
    Inventors: Donald Y. M. Leung, Janine M. Bilsborough, Jane A. Gross
  • Patent number: 8211879
    Abstract: The invention provides methods for decreasing or inhibiting herpesviridae (HV) infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with a herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo, or an adverse side effect of herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e.g., cationic steroid antimicrobial or CSA).
    Type: Grant
    Filed: September 7, 2010
    Date of Patent: July 3, 2012
    Assignees: Brigham Young University, National Jewish Medical and Research Center
    Inventors: Paul B. Savage, Donald Leung
  • Patent number: 7999082
    Abstract: Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
    Type: Grant
    Filed: February 10, 2005
    Date of Patent: August 16, 2011
    Assignees: National Jewish Medical and Research Center, MUSC Foundation for Research Development, The Regents of the University of Coloraodo
    Inventors: Vernon Michael Holers, Joshua M. Thurman, Christian Taube, Erwin W. Gelfand, Gary Steven Gilkeson
  • Publication number: 20110105452
    Abstract: The present invention relates, in one embodiment, to a method of preventing or treating diabetes using low molecular weight antioxidants. In a further embodiment, the invention relates to a method of protecting and/or enhancing viability of cells/tissues/organs during isolation (harvesting), preservation, expansion and/or transplantation. In yet another embodiment, the present invention relates to a method of inducing immune tolerance. The invention also relates to compounds and compositions suitable for use in such methods.
    Type: Application
    Filed: November 8, 2010
    Publication date: May 5, 2011
    Applicants: Aeolus Sciences, Inc., National Jewish Medical and Research Center, University of Colorado Health Sciences Center
    Inventors: Jon D. Piganelli, Kathryn Haskins, Sonia C. Flores, James D. Crapo, Brian J. day, Ronald G. Gill, Richard Gammans, Manisha Patel
  • Publication number: 20110002980
    Abstract: This invention relates to a vaccine and a method for immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated with allergic inflammation, an infectious disease, or a condition associated with a deleterious activity of a self-antigen. Also disclosed are therapeutic compositions useful in such a method.
    Type: Application
    Filed: April 8, 2010
    Publication date: January 6, 2011
    Applicant: NATIONAL JEWISH MEDICAL AND RESEARCH CENTER
    Inventors: STEVEN W. DOW, ROBYN E. ELMSLIE, JURGEN KARL JOHANNES SCHWARZE, ERWIN W. GELFAND
  • Publication number: 20110003304
    Abstract: Disclosed is a rapid, non-invasive and highly specific and sensitive diagnostic assay for the identification of individuals with autoimmune chronic urticaria, which makes use of CD203c, and in some embodiments, additional proteins, as a marker for the disease. Test kits for diagnosis of an individual suspected of having autoimmune chronic urticaria are also disclosed. Also disclosed are a method of identifying compounds useful for treating autoimmune chronic urticaria and a method of treating autoimmune chronic urticaria.
    Type: Application
    Filed: June 29, 2010
    Publication date: January 6, 2011
    Applicant: National Jewish Health (formerly National Jewish Medical and Research Center)
    Inventors: Ronald J. Harbeck, Karen Mary Andrews, Donald MacGlashan, JR.
  • Publication number: 20100279351
    Abstract: This invention generally relates to methods for the production of antibody producing cells and antibodies in protooncogene expressing animals. The invention also relates to methods for the efficient production of antibodies specific for antigens that are normally subject to immunological constraints such as self tolerance. The invention further relates to the production of antibody producing cells and antibodies without the need for the conventional fusing of antibody producing B cells with a myeloma fusion partner.
    Type: Application
    Filed: March 13, 2008
    Publication date: November 4, 2010
    Applicant: NATIONAL JEWISH MEDICAL AND RESEARCH CENTER
    Inventors: Yosef Refaeli, Brian Curtis Turner
  • Publication number: 20100272739
    Abstract: Disclosed is a method for regulation of airway hyperresponsiveness by modulating the action of ?? T cells in a patient. Also disclosed are methods for identifying compounds that regulate airway hyperresponsiveness by modulating ?? T cell action.
    Type: Application
    Filed: July 21, 2009
    Publication date: October 28, 2010
    Applicant: NATIONAL JEWISH MEDICAL AND RESEARCH CENTER
    Inventors: Erwin Gelfand, Willi K. Born, Michael F. Lahn, Arihiko Kanehiro
  • Publication number: 20100266600
    Abstract: The present invention relates to predicting therapeutic response of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cells in atopic dermatitis. The invention also includes methods of predicting a therapeutically responsive patient population.
    Type: Application
    Filed: March 19, 2010
    Publication date: October 21, 2010
    Applicants: ZymoGenetics, Inc., National Jewish Medical Research Center
    Inventors: Donald Y.M. Leung, Janine Bilsborough, Jane A. Gross
  • Patent number: 7754705
    Abstract: The invention provides methods for decreasing or inhibiting poxvirus infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with poxvirus infection or pathogenesis in vitro, ex vivo or in vivo, or an adverse side effect of poxvirus infection or pathogenesis in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e.g., cationic steroid antimicrobial or CSA).
    Type: Grant
    Filed: January 31, 2007
    Date of Patent: July 13, 2010
    Assignees: Brigham Young University, National Jewish Medical and Research Center
    Inventors: Paul B. Savage, Donald Y Leung
  • Patent number: 7741300
    Abstract: This invention relates to a vaccine and a method for immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated with allergic inflammation, an infectious disease, or a condition associated with a deleterious activity of a self-antigen. Also disclosed are therapeutic compositions useful in such a method.
    Type: Grant
    Filed: December 27, 2005
    Date of Patent: June 22, 2010
    Assignee: National Jewish Medical and Research Center
    Inventors: Steven W. Dow, Robyn E. Elmslie, Jurgen Karl Johannes Schwarze, Erwin W. Gelfand
  • Patent number: 7718618
    Abstract: Provided are peptide and peptide consensus sequences, which inhibit bacterial growth and/or viral growth and mimic the activity of LL-37, CRAMP, and/or FALL-39. The peptides are useful as antimicrobials, anti-inflammatories and anti-viral agents.
    Type: Grant
    Filed: October 20, 2004
    Date of Patent: May 18, 2010
    Assignees: The Regents of the University of California, National Jewish Medical and Research Center
    Inventors: Richard L. Gallo, Masamoto Murakami, Donald Y.M. Leung
  • Publication number: 20090093401
    Abstract: Disclosed are Cystatin C (CysC) homologues, including CystC homologues that act as antagonists or inhibitors of transforming growth factor-? (TGF-?). Also disclosed are methods to identify CystC homologues that are antagonists or inhibitors of TGF-? and compositions and therapeutic methods using CystC and homologues thereof to regulate the activity of TGF-?, and TGF-?-mediated tumor malignancy and invasion and other TGF-?-mediated fibrotic or proliferative conditions and diseases.
    Type: Application
    Filed: September 10, 2007
    Publication date: April 9, 2009
    Applicant: NATIONAL JEWISH MEDICAL AND RESEARCH CENTER
    Inventor: William P. Schiemann
  • Patent number: 7498047
    Abstract: Methods for therapy of cystic fibrosis and other conditions are provided. The methods comprise one or more agents capable of increasing thiol-containing compound transport via a transporter system (i.e. ABC transporters such as MDR-1 or MRP-2) in cells. Other embodiments include the use of agents to modulate transport of thiol-containing compounds within the cell. Therapeutic methods involve the administration of such agents to a patient afflicted with cystic fibrosis and/or another condition responsive to stimulation of thiol-containing compound transport.
    Type: Grant
    Filed: August 24, 2005
    Date of Patent: March 3, 2009
    Assignee: National Jewish Medical and Research Center
    Inventors: Brian J. Day, Richard T. Sawyer, Lee S. Newman
  • Publication number: 20080306000
    Abstract: Disclosed are TALL-1 and TALL-1 receptor protein homologues (agonists and antagonists) designed based on the three-dimensional structure of sTALL-1, eBCMA and eBAFF-R; agonist homologues of APRIL; methods of using wild-type APRIL to inhibit the activity of TALL-1; compositions comprising such homologues, nucleic acid molecules encoding such homologues, and therapeutic methods of using such compounds and compositions. Also disclosed are crystalline complexes of sTALL-1 and sTALL-1 in complex with either BCMA or BAFF-R; models of three-dimensional structures of such crystalline complexes and related structures, methods of drug design using any portion of such structures; methods of design and/or identification of regulatory peptides derived from the such structures; compounds identified by drug design using such structures; and the use of such compounds in therapeutic compositions and methods.
    Type: Application
    Filed: April 3, 2008
    Publication date: December 11, 2008
    Applicant: NATIONAL JEWISH MEDICAL AND RESEARCH CENTER
    Inventors: Gongyi Zhang, Hong-Bing Shu, Yingfang Liu, Liangguo Xu
  • Publication number: 20080248025
    Abstract: This invention generally relates to methods to treat conditions and diseases associated with interleukin-17 (IL-17) production. The invention also relates to methods of inhibiting ?? T cells, and particularly, a subset of ?? T cells that produce IL-17.
    Type: Application
    Filed: March 21, 2008
    Publication date: October 9, 2008
    Applicant: NATIONAL JEWISH MEDICAL AND RESEARCH CENTER
    Inventors: Christina Roark, Rebecca L. O'Brien, Willi K. Born
  • Publication number: 20080242640
    Abstract: The invention generally relates to methods to inhibit inflammation or pathogen infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention also relates to methods to prevent or inhibit respiratory syncytial virus (RSV) infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention further relates to compositions comprising randomly mixed surfactant lipids and methods to produce the compositions.
    Type: Application
    Filed: March 28, 2008
    Publication date: October 2, 2008
    Applicant: NATIONAL JEWISH MEDICAL AND RESEARCH CENTER
    Inventor: Dennis R. Voelker